Osteoporotic fractures exact a dreadful toll of pain, disability, and expense.
Because virtually the entire population is at risk for osteoporosis, inexpensive public health approaches are needed to help prevent the condition, but these are not well developed. Pharmacologic treatment of the entire population would be prohibitively expensive, so risk assessment is needed to employ costly drugs more efficiently.
Screening itself may be expensive, however, and efforts continue to define cost-effective approaches to the identification and treatment of individual patients at high risk for osteoporotic fractures.
Osteoporotic fractures pose an enormous public health problem, and a variety of interventions are needed to reduce their impact on society. The only rationale for patient risk assessment is to employ these interventions more efficiently. However, osteoporosis screening tests have costs, and the long-term benefits of osteoporosis treatment may be uncertain. This creates a need to consider the cost of risk assessment and the cost of treatment as well as the cost savings from any fractures that might be averted.
KeywordsOsteoporotic Fracture Osteoporosis Treatment Public Health Approach National Osteoporosis Foundation Individual Risk Assessment
Unable to display preview. Download preview PDF.
- Eddy D, Johnston CC, Cummings SR, et al. (1998) Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 8(supplement 4): 1–88.Google Scholar
- Hoerger TJ, Downs KE, Lakshmanan MC, et al. (1999) Healthcare use among US women aged 45 and older: total costs and costs for selected postmenopausal health risks. J Womens Health Gend Based Med 8: 1077–1089.Google Scholar
- Tengs TO, Adams ME, Pliskin JS, et al. (1995) Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 15: 369–390.Google Scholar
- Torgerson DJ, Kanis JA (1995) Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. QJ Med 88: 135–139.Google Scholar
- U.S. Congress, Office of Technology Assessment. Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy, Volume I: Cost-Effectiveness Analysis, OTABP-H-160, Washington, DC: U.S. Government Printing Office, August 1995.Google Scholar